Ferroptosis in cardiovascular disease - 05/01/24
Abstract |
In the 21st century, cardiovascular disease (CVD) has become one of the leading causes of death worldwide. The prevention and treatment of CVD remain pressing scientific issues. Several recent studies have suggested that ferroptosis may play a key role in CVD. Most studies conducted thus far on ferroptosis and CVD have supported the link. Ferroptosis mediated by different signaling and metabolic pathways can lead to ischemic heart disease, myocarditis, heart failure, ischemia-reperfusion injury, and cardiomyopathy. Still, the specific mechanism of ferroptosis in CVD, the particular organ areas affected, and the stage of disease involved need to be further studied. Therefore, understanding the mechanisms regulating ferroptosis in CVD may improve disease management. Throughout this review, we summarized the mechanism of ferroptosis and its effect on the pathogenesis of CVD. We also predicted and discussed future research directions, aiming to provide new ideas and strategies for preventing and treating CVD.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Ferroptosis is a new risk factor for cardiovascular disease (CVD). |
• | The pathogenesis of CVD is complex and involves multiple cell death types. |
• | Ferroptosis is closely related to other types of programmed cell death. |
• | Targeting ferroptosis is a potential strategy for preventing and treating CVD. |
Abbreviations : 7-KC, AA, ACSL4, AsIV, ATF4, BACH1, Cbs, CHOP, Cgl, CoQ10, COVID-19, CSE, CVD, Cys-Cys, Dex, DOX, DMT1, DXZ, ECG, ECs, EIF2α, elF2α, ERS, Fer-1, FPN1, FSP1, FTH1, FTL, HIF-1, I/R, Lcn2, LDL, LIP, LOOHs, LOX, Glu, Gly, GPXs, GSH, GLS2, GSSG, HF, HFD, HIF, HO-1, HSP90, HSPB1, IFN, ILH, IREB2, IRP, L-Cys, LPC, LPCAT3, LPS, MCAO, MI, MON-p53, NAC, NADPH, NCOA4, NOX, Nrf2, NTBI, OIF, PCBP, PCD, PERK, PEs, Ptgs2, PUFA, PUFA-CoA, PUMA, ROS, SFXN1, SLC1A5, SLC3A2, SLC38A1, SLC7A11, STEAP3, TF, TFR1, TLR4, TRAIL, TRIF, TTCC, UPR, VEGF, VSMCs, ZIPs
Keywords : Ferroptosis, Cardiovascular disease, Abnormal iron metabolism, Lipid peroxidation, Treatment strategies
Plan
Vol 170
Article 116057- janvier 2024 Retour au numéro
Article précédent
- Natural products in traditional Chinese medicine: molecular mechanisms and therapeutic targets of renal fibrosis and state-of-the-art drug delivery systems
- Li Song, Wei Zhang, Shi-yun Tang, Si-min Luo, Pei-yu Xiong, Jun-yu Liu, Heng-chang Hu, Ying-qi Chen, Bo Jia, Qian-hua Yan, Song-qi Tang, Wei Huang
- Molecular mechanism of α-Hederin in tumor progression
- Dandan Meng, Meng Ren, Maofeng Li, Min Wang, Wei Geng, Qingxin Shang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?